《临床肝胆病杂志》2015年1-12期“重点号”选题

为使作者了解我刊的编辑出版计划,及时地为我刊惠赐稿件,我刊编委会确定了2015年1-12期"重点号"选题:1.中西医结合肝胆胰疾病;2.自身免疫性肝病;3.肝纤维化及肝硬化;4.乙型肝炎;5.胰腺疾病;6.原发性肝癌;7.非酒精性脂肪性肝病;8.小儿肝胆胰疾病;9.肝衰竭与人工肝;10.胆汁淤积和胆道疾病;11.丙型肝炎;12.肝移植。     

《临床肝胆病杂志》2016年1-12期“重点号”选题

正为使作者了解我刊的编辑出版计划,及时地为我刊惠赐稿件,我刊编委会确定了2016年1-12期"重点号"选题:1.肝癌的介入治疗;2.门静脉高压症;3.脂肪肝与代谢综合征;4.中西医结合肝胆胰疾病;5.胰腺疾病;6.肝纤维化及肝硬化;7.无;8.无;9.肝衰竭;10.肝病免疫和自身免疫性肝病;11.乙型肝炎抗病毒治疗;12.肝胆胰影像。     

本刊2014年1～11期“重点号”选题

<正>为使作者了解我刊的编辑出版计划,及时地为我刊惠赐稿件,《临床肝胆病杂志》编委会确定了2014年1~11期"重点号"选题:1.肝移植;2.酒精性肝病;3.肝胆胰肿瘤;4.中西医结合肝胆胰疾病;5.自身免疫性肝病;6.丙型肝炎;7.肝纤维化及肝硬化;8.胰腺疾病;9.肝病免疫和细胞治疗;10.肝衰竭;11.胆道疾病。     

本刊2014年1~11期“重点号”选题预告

<正>为使作者了解我刊的编辑出版计划,及时地为我刊惠赐稿件,《临床肝胆病杂志》编委会确定了2014年1~11期"重点号"选题:1.肝移植;2.酒精性肝病;3.肝胆胰肿瘤;4.中西医结合肝胆胰疾病;5.自身免疫性肝病;6.丙型肝炎;7.肝纤维化及肝硬化;8.胰腺疾病;9.肝病免疫和细胞治疗;10.肝衰竭;11.胆道疾病。     

Cardioprotective Effect of Angiotensin n Receptor Antagonist on Perfused Ischemic Reperfusion Injury of Whole Isolated Rat Hearts

Objectives Investigated the cardioprotective and mechanisms of losartan on whole isolated ischemic reperfused rat heart. Methods Langendorff perfused systems was used to investigate losartan effect on whole isolated rat hearts in CPK, LDH, MDA, SOD, ang II and arrhythmia. Results Losartan decreased incidence of arrhythmia, improved atrial ventricular block recovery in reperfu-sion period, during ischemic period, CPK and LDH in I/R group increased significantly compared with control group, 51. 33±27. 02 vs 22. 42 ± 13. 33, 31. 80 ±4.56 vs 22. 28 ± 15. 96, respectively, but greatly decreased in losartan group compared with I/R group, 23. 90±21.74 vs 51. 33 ±27. 02 and 11. 50 ±13. 20 vs 31. 80 ±4. 56, respectively. During reperfusion period CPK, LDH increased significantly in I/R group compared with control group, 49. 11 ± 20. 63 vs 12. 14 ±5.92 and 28. 70±4. 69 vs 23. 10±21. 38, respectively, but decreased greatly in losartan group compared with I/R group, 39. 40 ± 9. 60 vs 49. 11 ± 20.63 an     

Effects of transmitters and interleukin-10 on rat hepatic fibrosis induced by CCl4

AIM: To study the effects of transmitters ET, AgⅡ, PGI2,CGRP and GG on experimental rat hepatic fbrosis and the antifibrogenic effects of IL-10.METHODS: One hundred SD rats were randomly divided into 3 groups: control group (N): intraperitoneal injection with saline 2 ml.kg^-1 twice a week; the fibrogenesis group (C): intraperitoneal injection with 50 % CC14 2 ml.kg^-1 twice a week; IL-10 treated group (E): besides same dosage of CC14 given, intraperitoneal injection with IL-10 4 ug.kg^-1 from the third week. In the fifth, the seventh and the ninth week,rats in three groups were selected randomly to collect plasma and liver tissues. The levels of ET, AgⅡ, PGI2, CGRP and GG were assayed by radioimmunoassay (RIA). The liver fibrosis was observed with silver staining.RESULTS: The hepatic fibrosis was developed with the increase of the injection frequency of CC14. The ET, AgⅡ, PGI2, CGRP and GG levels in serum of group N were 71.84&#177;60.2 ng.L^-1,76.21&#177;33.3 ng.L^-1, 313.03&#177;101.71 ng.L^-1, 61.97&#177;21.4 ng.L^-1 and 33.62&#177;14.37 ng.L^-1, respectively; the levels of them in serum of group C were 523.30&#177;129.3 ng.L^-1, 127.24&#177;50.0 ng.L^-1,648.91&#177;357.29 ng.L^-1, 127.15&#177;62.0 ng&#183;L^-1 and 85.26&#177;51.83ng.L^-1, respectively; the levels of them in serum of group E were 452.52&#177;99.5 ng.L^-1, 90.60&#177;44.7 ng.L^-1, 475.57&#177;179.70ng.L^-1, 102.2&#177;29.7 ng.L^-1 and 38.05&#177;19.94 ng.L^-1, respectively.The histological examination showed that the degrees of the rats liver fibrosis in group E were lower than those in group C.CONCLUSION: The transmitters ET, AgⅡ, PGI2, CGRP and GG play a significant role in the rat hepatic fibrosis induced by CCl4, IL-10 has the antagonistic action on these transmitters and can relieve the degree of the liver fibrosis.     

The effect of repaglinide on blood glucose and islet β-cell function in newly diagnosed type 2 diabetic patients

Objective To explore the effect of repaglinide intensive treatment on islet β-cell function and long-term control of blood glucose in newly diagnosed type 2 diabetic patients. Methods Self-control and inter-group control prospective study was conducted in 80 newly diagnosed type 2 diabetic patients who were treated with short-term repaglinide intensive treatment and islet β-cell function was assessed by 75 g oral glucose tolerance test (OGTT) before and after repaglinide treatment. The changes of △I30/△G30 ratio, blood lipid, HOMA A and HOMA B were examined. Results After treatment, in successful group, middle group and defeat group, the fasting plasma glucose levels were decreased from 8.9±1.5, 8.6±1.6,9.0±2.0 to 5.0±1.4,6.3±0. 7,6.5±0. 9 mmol/L, 0. 5 h postprandial glucose levels were decreased from (12.6±1.6, 12.6±1.5, 12.4±1.3 to 8.4±1.0, 6.8±0. 7, 8. 6±0. 9)mmol/L,and 2 h postprandial glucose levels were decreased from (13.0±1.2, 13. 1±1.3, 13. 3±1.4 to 9.2±0.9, 6.6±0. 7, 9.2±0. 9)mmol/L,respectively (all P <0. 005). The ratio of △I30/△G30 was increased froml. 69±0. 31, 1.72±0. 33, 1.79±0. 36 to 4. 47±0. 62, 4. 42±0.46,12. 00±0.46 in the three groups, respectively (P<0.05). HOMA B was significantly improved (P<0. 05), while triglycerides and HOMA A were decreased(P<0. 05). The levels of fasting blood glucose and postprandial blood glucose in 21 patients were maintained within normal range for more than six months. There were significant differences in the ratio of △I30/△G30, age, repaglinide dosage and the time of reaching target of glucose [4.47±0.62 vs. 2. 0± 0.46; 39±8 vs. 56±9; 2.0±1.5 vs. 5.0±2.5; 32.4±8.0 vs. 53.3±7.6; all P<0.05] between successful group and defeat group. Conclusions The short-term intensive treatment with repaglinide can significantly improve the early secretion phase of insulin and the islet β-cell function, reconstruct of the physiological model of insulin secretion and relieve the disease.     

The effect of repaglinide on blood glucose and islet β-cell function in newly diagnosed type 2 diabetic patients

Objective To explore the effect of repaglinide intensive treatment on islet β-cell function and long-term control of blood glucose in newly diagnosed type 2 diabetic patients. Methods Self-control and inter-group control prospective study was conducted in 80 newly diagnosed type 2 diabetic patients who were treated with short-term repaglinide intensive treatment and islet β-cell function was assessed by 75 g oral glucose tolerance test (OGTT) before and after repaglinide treatment. The changes of △I30/△G30 ratio, blood lipid, HOMA A and HOMA B were examined. Results After treatment, in successful group, middle group and defeat group, the fasting plasma glucose levels were decreased from 8.9±1.5, 8.6±1.6,9.0±2.0 to 5.0±1.4,6.3±0. 7,6.5±0. 9 mmol/L, 0. 5 h postprandial glucose levels were decreased from (12.6±1.6, 12.6±1.5, 12.4±1.3 to 8.4±1.0, 6.8±0. 7, 8. 6±0. 9)mmol/L,and 2 h postprandial glucose levels were decreased from (13.0±1.2, 13. 1±1.3, 13. 3±1.4 to 9.2±0.9, 6.6±0. 7, 9.2±0. 9)mmol/L,respectively (all P <0. 005). The ratio of △I30/△G30 was increased froml. 69±0. 31, 1.72±0. 33, 1.79±0. 36 to 4. 47±0. 62, 4. 42±0.46,12. 00±0.46 in the three groups, respectively (P<0.05). HOMA B was significantly improved (P<0. 05), while triglycerides and HOMA A were decreased(P<0. 05). The levels of fasting blood glucose and postprandial blood glucose in 21 patients were maintained within normal range for more than six months. There were significant differences in the ratio of △I30/△G30, age, repaglinide dosage and the time of reaching target of glucose [4.47±0.62 vs. 2. 0± 0.46; 39±8 vs. 56±9; 2.0±1.5 vs. 5.0±2.5; 32.4±8.0 vs. 53.3±7.6; all P<0.05] between successful group and defeat group. Conclusions The short-term intensive treatment with repaglinide can significantly improve the early secretion phase of insulin and the islet β-cell function, reconstruct of the physiological model of insulin secretion and relieve the disease.     

《临床肝胆病杂志》2015年1-10期“重点号”选题

为使作者了解我刊的编辑出版计划,及时地为我刊惠赐稿件,我刊编委会确定了2015年1-10期"重点号"选题:1.中西医结合肝胆胰疾病;2.自身免疫性肝病;3.肝纤维化及肝硬化;4.乙型肝炎;5.胰腺疾病;6.原发性肝癌;7.非酒精性脂肪性肝病;8.小儿肝胆胰疾病;9.肝衰竭;10.胆汁淤积和胆道疾病。     

本刊2014年1~11期“重点号”选题预告

<正>为使作者了解我刊的编辑出版计划,及时地为我刊惠赐稿件,《临床肝胆病杂志》编委会确定了2014年1~11期"重点号"选题:1.肝移植;2.酒精性肝病;3.肝胆胰肿瘤;4.中西医结合肝胆胰疾病;5.自身免疫性肝病;6.丙型肝炎;7.肝纤维化及肝硬化;8.胰腺疾病;9.肝病免疫和细胞治疗;10.肝衰竭;11.胆道疾病。为本刊重点号的投稿请注明"***重点号投稿"字样。     

老年人冠心病确诊前血脂变化研究

目的　研究老年人冠心病确诊前血脂变化特点。方法　确诊冠心病当年及前 4年的总胆固醇 (TC)、甘油三酯 (TG)、低密度脂蛋白胆固醇 (L DL )和高密度脂蛋白胆固醇 (HDL)水平并进行比较。结果　冠心病组与无冠心病组血脂比较 :TC5.1 5± 0 .91 mmol/ L与 5.0 2± 0 .98mmol/L,TG1 .55± 0 .86mmol/ L与 1 .53± 0 .96mmol/ L,HDL 1 .33± 0 .34mmol/ L与 1 .46± 0 .45mmol/ L,LDL3.1 2± 0 .94mmol/ L与 2 .73± 0 .79mmol/L ,LDL/ HDL2 .53± 1 .0 9与 1 .91± 0 .66。研究组确诊当年、前 1年、前 2年、前 3年和前 4年的血脂变化 :HDL1 .33± 0 .34、1 .30± 0 .37、1 .34± 0 .31、1 .32± 0 .35和 1 .43± 0 .44;LDL3.1 2± 0 .94、3.2 3± 0 .98、3.0 4± 0 .86、2 .33± 0 .99和 2 .89± 0 .96。结论　冠心病危险因子在确诊冠心病前的第1年最高 ,提示在进入老年期血脂仍旧在改变 ,冠心病危险因子不断升高 ,保护因子不断降低 ;老年人仍有必要采取干预血脂措施。     

病毒性肝炎后肝硬化患者肠道的通透性

目的　探讨病毒性肝炎后肝硬化与肠道通透性的关系。方法　参照Holt等的方法测定96例肝硬化患者血清中二胺氧化酶 (DAO)活性 ;并用气相色谱法测定服用乳果糖、甘露醇后在尿中的分泌率 ,用以评价患者肠黏膜的组织结构及其功能。结果　患者Child +Pugh分级各组中DAO的活性和乳果糖 /甘露醇 (L/M)比值与对照组间差异有显著性 (DAOA级 4 .6 8± 0 .97,B级 6 .0 5± 1.0 2 ,C级7.80± 1.34比 3.98± 0 .93,P <0 .0 5～ 0 .0 0 5 ;L/MA级 0 .0 39± 0 .0 0 7,B级 0 .0 6 8± 0 .0 12 ,C级 0 .119±0 .0 2 3比 0 .0 33± 0 .0 0 4 ,P <0 .0 5～ 0 .0 0 5 )。并发自发性细菌性腹膜炎 (SBP)组与非SBP组间差异有显著性 (DAO 7.6 7± 3.0 3比 4 .96± 0 .95 ,P <0 .0 0 5 ;L/M 0 .10 7± 0 .0 6 0比 0 .0 4 2± 0 .0 0 7,P <0 .0 0 5 ) ;非SBP组与对照组间差异亦具有显著性 (DAO 4 .96± 0 .95比 3.98± 0 .93,P <0 .0 5 ,L/M 0 .0 4 2± 0 .0 0 7比0 .0 33± 0 .0 0 4 ,P <0 .0 5 )。结论　病毒性肝炎后肝硬化患者肠道黏膜受损是导致SBP的主要原因之一 ,测定病毒性肝硬化患者血清中DAO活性及尿中L/M比值可以探知肠黏膜结构及其功能有无损害。     

The effect of repaglinide on blood glucose and islet β-cell function in newly diagnosed type 2 diabetic patients

Objective To explore the effect of repaglinide intensive treatment on islet β-cell function and long-term control of blood glucose in newly diagnosed type 2 diabetic patients. Methods Self-control and inter-group control prospective study was conducted in 80 newly diagnosed type 2 diabetic patients who were treated with short-term repaglinide intensive treatment and islet β-cell function was assessed by 75 g oral glucose tolerance test (OGTT) before and after repaglinide treatment. The changes of △I30/△G30 ratio, blood lipid, HOMA A and HOMA B were examined. Results After treatment, in successful group, middle group and defeat group, the fasting plasma glucose levels were decreased from 8.9±1.5, 8.6±1.6,9.0±2.0 to 5.0±1.4,6.3±0. 7,6.5±0. 9 mmol/L, 0. 5 h postprandial glucose levels were decreased from (12.6±1.6, 12.6±1.5, 12.4±1.3 to 8.4±1.0, 6.8±0. 7, 8. 6±0. 9)mmol/L,and 2 h postprandial glucose levels were decreased from (13.0±1.2, 13. 1±1.3, 13. 3±1.4 to 9.2±0.9, 6.6±0. 7, 9.2±0. 9)mmol/L,respectively (all P <0. 005). The ratio of △I30/△G30 was increased froml. 69±0. 31, 1.72±0. 33, 1.79±0. 36 to 4. 47±0. 62, 4. 42±0.46,12. 00±0.46 in the three groups, respectively (P<0.05). HOMA B was significantly improved (P<0. 05), while triglycerides and HOMA A were decreased(P<0. 05). The levels of fasting blood glucose and postprandial blood glucose in 21 patients were maintained within normal range for more than six months. There were significant differences in the ratio of △I30/△G30, age, repaglinide dosage and the time of reaching target of glucose [4.47±0.62 vs. 2. 0± 0.46; 39±8 vs. 56±9; 2.0±1.5 vs. 5.0±2.5; 32.4±8.0 vs. 53.3±7.6; all P<0.05] between successful group and defeat group. Conclusions The short-term intensive treatment with repaglinide can significantly improve the early secretion phase of insulin and the islet β-cell function, reconstruct of the physiological model of insulin secretion and relieve the disease.     

The effect of repaglinide on blood glucose and islet β-cell function in newly diagnosed type 2 diabetic patients

Objective To explore the effect of repaglinide intensive treatment on islet β-cell function and long-term control of blood glucose in newly diagnosed type 2 diabetic patients. Methods Self-control and inter-group control prospective study was conducted in 80 newly diagnosed type 2 diabetic patients who were treated with short-term repaglinide intensive treatment and islet β-cell function was assessed by 75 g oral glucose tolerance test (OGTT) before and after repaglinide treatment. The changes of △I30/△G30 ratio, blood lipid, HOMA A and HOMA B were examined. Results After treatment, in successful group, middle group and defeat group, the fasting plasma glucose levels were decreased from 8.9±1.5, 8.6±1.6,9.0±2.0 to 5.0±1.4,6.3±0. 7,6.5±0. 9 mmol/L, 0. 5 h postprandial glucose levels were decreased from (12.6±1.6, 12.6±1.5, 12.4±1.3 to 8.4±1.0, 6.8±0. 7, 8. 6±0. 9)mmol/L,and 2 h postprandial glucose levels were decreased from (13.0±1.2, 13. 1±1.3, 13. 3±1.4 to 9.2±0.9, 6.6±0. 7, 9.2±0. 9)mmol/L,respectively (all P <0. 005). The ratio of △I30/△G30 was increased froml. 69±0. 31, 1.72±0. 33, 1.79±0. 36 to 4. 47±0. 62, 4. 42±0.46,12. 00±0.46 in the three groups, respectively (P<0.05). HOMA B was significantly improved (P<0. 05), while triglycerides and HOMA A were decreased(P<0. 05). The levels of fasting blood glucose and postprandial blood glucose in 21 patients were maintained within normal range for more than six months. There were significant differences in the ratio of △I30/△G30, age, repaglinide dosage and the time of reaching target of glucose [4.47±0.62 vs. 2. 0± 0.46; 39±8 vs. 56±9; 2.0±1.5 vs. 5.0±2.5; 32.4±8.0 vs. 53.3±7.6; all P<0.05] between successful group and defeat group. Conclusions The short-term intensive treatment with repaglinide can significantly improve the early secretion phase of insulin and the islet β-cell function, reconstruct of the physiological model of insulin secretion and relieve the disease.     

The effect of repaglinide on blood glucose and islet β-cell function in newly diagnosed type 2 diabetic patients

Objective To explore the effect of repaglinide intensive treatment on islet β-cell function and long-term control of blood glucose in newly diagnosed type 2 diabetic patients. Methods Self-control and inter-group control prospective study was conducted in 80 newly diagnosed type 2 diabetic patients who were treated with short-term repaglinide intensive treatment and islet β-cell function was assessed by 75 g oral glucose tolerance test (OGTT) before and after repaglinide treatment. The changes of △I30/△G30 ratio, blood lipid, HOMA A and HOMA B were examined. Results After treatment, in successful group, middle group and defeat group, the fasting plasma glucose levels were decreased from 8.9±1.5, 8.6±1.6,9.0±2.0 to 5.0±1.4,6.3±0. 7,6.5±0. 9 mmol/L, 0. 5 h postprandial glucose levels were decreased from (12.6±1.6, 12.6±1.5, 12.4±1.3 to 8.4±1.0, 6.8±0. 7, 8. 6±0. 9)mmol/L,and 2 h postprandial glucose levels were decreased from (13.0±1.2, 13. 1±1.3, 13. 3±1.4 to 9.2±0.9, 6.6±0. 7, 9.2±0. 9)mmol/L,respectively (all P <0. 005). The ratio of △I30/△G30 was increased froml. 69±0. 31, 1.72±0. 33, 1.79±0. 36 to 4. 47±0. 62, 4. 42±0.46,12. 00±0.46 in the three groups, respectively (P<0.05). HOMA B was significantly improved (P<0. 05), while triglycerides and HOMA A were decreased(P<0. 05). The levels of fasting blood glucose and postprandial blood glucose in 21 patients were maintained within normal range for more than six months. There were significant differences in the ratio of △I30/△G30, age, repaglinide dosage and the time of reaching target of glucose [4.47±0.62 vs. 2. 0± 0.46; 39±8 vs. 56±9; 2.0±1.5 vs. 5.0±2.5; 32.4±8.0 vs. 53.3±7.6; all P<0.05] between successful group and defeat group. Conclusions The short-term intensive treatment with repaglinide can significantly improve the early secretion phase of insulin and the islet β-cell function, reconstruct of the physiological model of insulin secretion and relieve the disease.     

用心阻抗法测量冠心病患者不同时期心功能

目的　研究冠心病不同时期心功能特点。方法　应用心脏血流动力监测仪 ,通过心阻抗法 ,选取 SV、CI、EF、PEP、LVET、HI、AMP A、A/C、PCWP、L VEDP、TPR为研究内容 ,统计分析心绞痛组与对照组、心力衰竭组与心绞痛组各参数比较 P<0 .0 5时认为有显著性差异。结果　稳定型心绞痛组与对照组 SV 5 8.31± 12 .10 ,比 83.61± 17.83,P<0 .0 1;CI 2 .37± 0 .89比 4.12±0 .5 7,P<0 .0 5 ;HI8.0 8± 3.12比 16.64± 5 .81,P<0 .0 1;A/C0 .5 5± 0 .2 1比 0 .33± 0 .15 ,P<0 .0 5 ;TPR15 92± 30 8比 961±10 2 ,P<0 .0 1。心力衰竭组与稳定型心绞痛组比较 ,所有参数均有显著性差异。结论　冠心病处于心绞痛阶段时虽无临床心力衰竭表现 ,其舒缩功能已开始下降。冠心病处于心力衰竭阶段时 ,心脏舒缩功能全面失代偿     

内地高辛、钠、钾、镁与高血压病胰岛素抵抗的相关性

目的 :探讨内地高辛及钠、钾、镁在高血压病胰岛素抵抗病理机制中的作用。方法 :测定 30例高血压病患者(EH组 )的空腹血浆葡萄糖 (FPG)、胰岛素 (FINS)水平 ,同时测定血清内地高辛 (EDX)及细胞内 Na+、 K+、 Mg2 +含量并与 2 6例正常血压对照者 (NC组 )作对照。结果 :EH组 FPG、FINS、EDX、Na+水平显著高于 NC组 (P<0 .0 5 ,<0 .0 1,<0 .0 1、 <0 .0 0 1) ,胰岛素敏感性指数 (ISI)、 K+、 Mg2 +显著低于 NC组 (P<0 .0 0 2 ,<0 .0 1,<0 .0 0 1) ;EH组 FINS与体重、体重指数 (BMI)、臀围、 EDX呈显著正相关 (r=0 .5 2 ,0 .35 ,0 .45 ,0 .41;P<0 .0 0 5 ,<0 .0 5 ,<0 .0 1,<0 .0 5 ) ,ISI与体重、BMI、臀围呈显著负相关 (r=- 0 .5 8,- 0 .42 ,- 0 .5 7;P<0 .0 0 1,<0 .0 5 ,<0 .0 1)。结论 :高血压患者血胰岛素水平与内地高辛、肥胖呈显著正相关 (P<0 .0 5～ <0 .0 0 5 ) ;ISI与肥胖呈显著负相关。     

骨细胞密度对骨生物力学性能的影响

Objective To investigate osteocyte density as a potential index of bone biomechanical property. Methods Forty 7-month-old female Sprague-Dawley rats were randomly group (EST) and sham operation group (SHAM). At 15 weeks postoperation, the compression test was performed on L5 vertebral body and micro-computed tomography (μ-CT) was used to estimate the three-dimensional bone mineral density (BMD) and three-dimensional microstructure parameters of L6 vertebral body. After fatigue damage testing, the L6 vertebral body was bulk-stained in 1% basic fuchsin and embedded in methylmethacrylate. Mounted bone slices were used to measure microcrack parameters and osteocyte density. Results At 15 weeks postoperation, osteocyte density (Ot. N/T. area) was significantly decreased in OVX group compared with SHAM group and EST group [(1268. 1 ±191.2)/mm2 vs. (1760. 8 ± 376.6)/mm2 and (1550. 9± 202.2)/mm2, F = 3.513,P<0. 05]. Maximum load (ML) was significantly decreased and the length of microcrack (Cr. Le) was significantly increased in OVX group compared with SHAM group, EST group and GEN group [(84. 4±16.9)N vs. (110.3±25.6),(103. 9±15. 8)and(110.1±4. 9)N; (58. 1±6.8) μm vs. (24.2±8. 1), (36. 5±9. 7)and(28.5±7. 5)μm, F=9. 561,3. 179, all P<0. 05]. Compared with SHAM group and EST group, bone trabecula connection density (Conn. D) was significantly decreased and trabecular separation (Tb. Sp) was significantly increased in OVX group [(47.4±7.4) m-3 vs. (71.8±16.0)and (74.0±12.7)m-3;(315.0±32.7)μm vs. (222. 5±21.7)and (273.3± 50.0)μm, F=7. 635,7. 007, all P<0. 05]. Bone mineral content (BMC) was lower in OVX group than that in SHAM group[(6.5±2. 2)g vs. (7. 9±1.2)g, P<0. 05]. When data in four groups were overall analyzed, Ot. N/T. Ar was positively correlated with ML, Conn. D and BMC (R2 = 0. 7874, 0. 1153, 0. 1309, all P<0. 05), but was negatively correlated with Cr. Le and Tb. Sp (R2 =0. 5738, 0. 3964, both P < 0.05). Conclusions Osteocyte plays a crucial role in maintaining bone biomechanical property and osteocyte density may be considered as a useful indicator for assessing bone biomechanical property.     

骨细胞密度对骨生物力学性能的影响

Objective To investigate osteocyte density as a potential index of bone biomechanical property. Methods Forty 7-month-old female Sprague-Dawley rats were randomly group (EST) and sham operation group (SHAM). At 15 weeks postoperation, the compression test was performed on L5 vertebral body and micro-computed tomography (μ-CT) was used to estimate the three-dimensional bone mineral density (BMD) and three-dimensional microstructure parameters of L6 vertebral body. After fatigue damage testing, the L6 vertebral body was bulk-stained in 1% basic fuchsin and embedded in methylmethacrylate. Mounted bone slices were used to measure microcrack parameters and osteocyte density. Results At 15 weeks postoperation, osteocyte density (Ot. N/T. area) was significantly decreased in OVX group compared with SHAM group and EST group [(1268. 1 ±191.2)/mm2 vs. (1760. 8 ± 376.6)/mm2 and (1550. 9± 202.2)/mm2, F = 3.513,P<0. 05]. Maximum load (ML) was significantly decreased and the length of microcrack (Cr. Le) was significantly increased in OVX group compared with SHAM group, EST group and GEN group [(84. 4±16.9)N vs. (110.3±25.6),(103. 9±15. 8)and(110.1±4. 9)N; (58. 1±6.8) μm vs. (24.2±8. 1), (36. 5±9. 7)and(28.5±7. 5)μm, F=9. 561,3. 179, all P<0. 05]. Compared with SHAM group and EST group, bone trabecula connection density (Conn. D) was significantly decreased and trabecular separation (Tb. Sp) was significantly increased in OVX group [(47.4±7.4) m-3 vs. (71.8±16.0)and (74.0±12.7)m-3;(315.0±32.7)μm vs. (222. 5±21.7)and (273.3± 50.0)μm, F=7. 635,7. 007, all P<0. 05]. Bone mineral content (BMC) was lower in OVX group than that in SHAM group[(6.5±2. 2)g vs. (7. 9±1.2)g, P<0. 05]. When data in four groups were overall analyzed, Ot. N/T. Ar was positively correlated with ML, Conn. D and BMC (R2 = 0. 7874, 0. 1153, 0. 1309, all P<0. 05), but was negatively correlated with Cr. Le and Tb. Sp (R2 =0. 5738, 0. 3964, both P < 0.05). Conclusions Osteocyte plays a crucial role in maintaining bone biomechanical property and osteocyte density may be considered as a useful indicator for assessing bone biomechanical property.     

《临床肝胆病杂志》2016年1-12期“重点号”选题

为使作者了解我刊的编辑出版计划,及时地为我刊惠赐稿件,我刊编委会确定了2016年1^-12期"重点号"选题:1.肝癌的介入治疗;2.门静脉高压症;3.脂肪肝与代谢综合征;4.中西医结合肝胆胰疾病;5.胰腺疾病;6.肝纤维化及肝硬化;7.无;8.无;9.肝衰竭;10.自身免疫性肝病;11.乙型肝炎抗病毒治疗;12.肝胆胰影像。为本刊重点号的投稿请注明"***重点号投稿"字样。对于围绕重点号选题的文章,本刊将择优优先发表。欢迎广大作者踊跃投稿。